Article | Published:

Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages

Acta Pharmacologica Sinica | Download Citation

Subjects

Abstract

Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease (IBD) characterized by complicated and relapsing inflammation in the gastrointestinal tract. SM934 is a water-soluble artemisinin analogue that shows anti-inflammatory and immuno-regulatory effects. In this study, we investigated the effects of SM934 on UC both in vivo and in vitro. A mouse model of colitis was established in mice by oral administration of 5% dextran sulfate sodium (DSS). SM934 (3, 10 mg/kg per day, ig) was administered to the mice for 10 days. After the mice were sacrificed, colons, spleens and mesenteric lymph nodes (MLNs) were collected for analyses. We showed that SM934 administration restored DSS-induced body weight loss, colon shortening, injury and inflammation scores. Furthermore, SM934 administration significantly decreased the disease activity index (DAI), histopathological scores, and myeloperoxidase (MPO) activities in colonic tissues. Moreover, SM934 administration dose-dependently decreased the mRNA and protein levels of DSS-induced pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α), and the percentage of macrophages and neutrophils in colon tissues. The effects of SM934 on LPS-stimulated RAW 264.7 cells and THP-1-derived macrophages were examined in vitro. Treatment with SM934 (0.8, 8, 80 μmol/L) dose-dependently decreased the production of pro-inflammatory mediators in LPS-stimulated RAW264.7 cells and THP-1-derived macrophages via inhibiting activation of the NF-κB signaling. Our results reveal the protective effects of SM934 on DSS-induced colitis can be attributed to its suppressing effects on neutrophils and macrophages and its inhibitory role in the NF-κB signaling, suggests that SM934 might be a potential effective drug for ulcerative colitis.

  • Subscribe to Acta Pharmacologica Sinica for full access:

    $576

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    . Inflammatory bowel disease. N Engl J Med 2002; 347: 417–29.

  2. 2.

    , . Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427–34.

  3. 3.

    , . Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007; 59: 1073–83.

  4. 4.

    , , , , , . Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 1995; 10: 387–95.

  5. 5.

    . Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329–42.

  6. 6.

    . The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 21–33.

  7. 7.

    , . Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 2006; 130: 67–87.

  8. 8.

    , , , , , , et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357–69.

  9. 9.

    , , , , , , et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 1998; 859: 149–59.

  10. 10.

    , , , . Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998–1004.

  11. 11.

    , , , , , , et al. Artemisinin analogue SM934 ameliorates the proteinuria and renal fibrosis in rat experimental membranous nephropathy. Acta Pharmacol Sin 2015; 36: 188–99.

  12. 12.

    , , , , , , et al. Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell. PLoS One 2013; 8: e74108.

  13. 13.

    , , , , , . Artemisinin analogue SM934 attenuate collagen-induced arthritis by suppressing T follicular helper cells and T helper 17 cells. Sci Rep 2016; 6: 38115.

  14. 14.

    , , , , , , et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011; 63: 2445–55.

  15. 15.

    , , , , , , et al. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. Cell Mol Immunol 2016; 13: 379–90.

  16. 16.

    , , , . Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br J Pharmacol 1999; 127: 1915–21.

  17. 17.

    , , , . Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 2014; 104: Unit 15 25.

  18. 18.

    , , , , , . Heme oxygenase-1 ameliorates dextran sulfate sodium-induced acute murine colitis by regulating Th17/Treg cell balance. J Biol Chem 2014; 289: 26847–58.

  19. 19.

    , . Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol 2014; 7: 111–32.

  20. 20.

    , , , , , , et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 2003; 124: 1381–94.

  21. 21.

    , , , . Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp 2012; (60). pii: 3678. doi: 10.3791/3678.

  22. 22.

    , . Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. Curr Protoc Immunol 2001; Chapter 3: Unit 3.19.

  23. 23.

    , , , , , , et al. (5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating Fcgamma receptor signaling. Acta Pharmacol Sin 2018; 39: 107–16.

  24. 24.

    , , , , , . SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 2009; 30: 1428–35.

  25. 25.

    , , , , , , et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 2009; 4: e6073.

  26. 26.

    , , , , , . CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation. Am J Pathol 2012; 181: 719–27.

  27. 27.

    , , . NF-kappaB in inflammatory bowel disease. J Intern Med 2008; 263: 591–6.

  28. 28.

    , , , , , , et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192–9.

  29. 29.

    . Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12: 205–17.

  30. 30.

    , , , , , . Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643–52.

  31. 31.

    , , , , . Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3–10.

  32. 32.

    , , . Water-soluble artemisinin derivatives as promising therapeutic immunosuppressants of autoimmune diseases. Cell Mol Immunol 2017 Sep 11. doi: 10.1038/cmi.2017.87.

  33. 33.

    , , , , , , et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011; 63: 2445–55.

  34. 34.

    , , , , , . Protective effects of wedelolactone on dextran sodium sulfate induced murine colitis partly through inhibiting the NLRP3 inflammasome activation via AMPK signaling. Biomed Pharmacother 2017; 94: 27–36.

  35. 35.

    , . The immune system and the gut microbiota: friends or foes? Nat Rev Immunol 2010; 10: 735–44.

  36. 36.

    , , , , . Role of inducible nitric oxide synthase in the regulation of neutrophil migration in zymosan-induced inflammation. Immunology 1998; 95: 625–30.

  37. 37.

    , , , , , . Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-kappaB activation. Int J Colorectal Dis 2009; 24: 5–12.

Download references

Acknowledgements

This work was supported by grants “Personalized Medicines-Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences, Grant No XDA12020107, National Science & Technology Major Project “New Drug Creation and Manufacturing Program”, China (No 2017ZX09101002-002-010), National Natural Science Foundation of China (NSFC): 81673445 and we are grateful to Dr Lin WANG (University of Michigan) who kindly contributed to the manuscript revision.

Author information

Affiliations

  1. Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    • Yu-xi Yan
    • , Qing Qi
    • , Xiao-qian Yang
    • , Feng-hua Zhu
    • , Shi-jun He
    • , Pei-lan He
    • , Chun-lan Feng
    • , Yan-wei Wu
    • , Heng Li
    • , Wei Tang
    •  & Jian-ping Zuo
  2. University of Chinese Academy of Sciences, Beijing 100049, China

    • Yu-xi Yan
    • , Heng Li
    • , Wei Tang
    •  & Jian-ping Zuo
  3. Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

    • Mei-juan Shao
    • , Yan-sheng Xu
    •  & Jian-ping Zuo

Authors

  1. Search for Yu-xi Yan in:

  2. Search for Mei-juan Shao in:

  3. Search for Qing Qi in:

  4. Search for Yan-sheng Xu in:

  5. Search for Xiao-qian Yang in:

  6. Search for Feng-hua Zhu in:

  7. Search for Shi-jun He in:

  8. Search for Pei-lan He in:

  9. Search for Chun-lan Feng in:

  10. Search for Yan-wei Wu in:

  11. Search for Heng Li in:

  12. Search for Wei Tang in:

  13. Search for Jian-ping Zuo in:

Corresponding authors

Correspondence to Wei Tang or Jian-ping Zuo.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/aps.2017.185

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.